DK1442019T3 - Amidderivater som glycogensynthasekinase 3- beta-inhibitorer - Google Patents

Amidderivater som glycogensynthasekinase 3- beta-inhibitorer

Info

Publication number: DK1442019T3
Authority: DK; Denmark
Prior art keywords: sub; sup; alkyl; hydrogen; polyhaloc
Prior art date: 2001-11-01

Application number

DK02790304T

Other languages

English (en)

Inventor

Eddy Jean Edgard Freyne

Marc Willems

Werner Constant Joha Embrechts

Paulus Joannes Lewi

Jan Heeres

Jonge Marc Rene De

Lucien Maria Henricus Koymans

Frederik Frans Desire Daeyaert

Michael Joseph Kukla

Hugo Alfons Gabriel Geerts

Rony Maria Nuydens

Marc Hubert Mercken

Donald William Jansse Ludovici

Paul Peter Maria Janssen

Graziella Maria Consta Janssen

Jasmin Josee Werner Janssen

Maroussia Godelieve Fr Janssen

Herwig Josephus Margar Janssen

Theodora Joanna Francisca Arts

Peter Jacobus Johan Buijnsters

Jean Fernand Armand J Lacrampe

Paul Adriaan Jan Decea Janssen

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-01

Filing date

2002-10-29

Publication date

2008-01-14

2002-10-29 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2008-01-14 Application granted granted Critical

2008-01-14 Publication of DK1442019T3 publication Critical patent/DK1442019T3/da

Links

102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title 1
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title 1
150000001408 amides Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
125000004414 alkyl thio group Chemical group 0.000 abstract 2
125000000304 alkynyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
150000001204 N-oxides Chemical class 0.000 abstract 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
125000003277 amino group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK02790304T 2001-11-01 2002-10-29 Amidderivater som glycogensynthasekinase 3- beta-inhibitorer DK1442019T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01204193		2001-11-01
PCT/EP2002/012067 WO2003037869A1 (en)	2001-11-01	2002-10-29	Amide derivatives as glycogen synthase kinase 3-beta inhibitors

Publications (1)

Publication Number	Publication Date
DK1442019T3 true DK1442019T3 (da)	2008-01-14

Family

ID=8181176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02790304T DK1442019T3 (da)	2001-11-01	2002-10-29	Amidderivater som glycogensynthasekinase 3- beta-inhibitorer

Country Status (21)

Country	Link
US (1)	US7183288B2 (da)
EP (1)	EP1442019B8 (da)
JP (1)	JP2005507419A (da)
KR (1)	KR20050040814A (da)
CN (1)	CN1582277A (da)
AT (1)	ATE375331T1 (da)
AU (1)	AU2002363174B2 (da)
BR (1)	BR0213791A (da)
CA (1)	CA2463821A1 (da)
DE (1)	DE60222921T2 (da)
DK (1)	DK1442019T3 (da)
EA (1)	EA007578B1 (da)
ES (1)	ES2294190T3 (da)
HU (1)	HUP0402330A3 (da)
IL (1)	IL161661A0 (da)
MX (1)	MXPA04004177A (da)
NO (1)	NO327097B1 (da)
NZ (1)	NZ531855A (da)
PL (1)	PL368917A1 (da)
PT (1)	PT1442019E (da)
WO (1)	WO2003037869A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1738797A (zh)	2002-11-19	2006-02-22	阿基里昂药品公司	取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
CN1972914A (zh)	2004-03-31	2007-05-30	詹森药业有限公司	作为组胺h3受体配合体的非咪唑杂环化合物
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US7456176B2 (en)	2004-04-08	2008-11-25	Targegen, Inc.	Benzotriazine inhibitors of kinases
TW200600492A (en)	2004-05-18	2006-01-01	Achillion Pharmaceuticals Inc	Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
MXPA06014747A (es)	2004-06-28	2007-02-16	Altana Pharma Ag	Pirimidinas 4,6-disustituidas y su uso como inhibidores de proteina cinasa.
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en)	2005-10-21	2011-07-26	Braincells Inc.	Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US7528143B2 (en)	2005-11-01	2009-05-05	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
CA2633740A1 (en) *	2005-12-22	2007-06-28	Crystalgenomics, Inc.	Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
KR101372941B1 (ko)	2006-05-30	2014-03-14	얀센 파마슈티카 엔.브이.	히스타민 ｈ３ 수용체 조절제로서의 치환된 피리딜 아미드 화합물
US8841334B2 (en) *	2006-05-31	2014-09-23	Abbvie Inc.	Compounds as cannabinoid receptor ligands and uses thereof
CN101448800A (zh) *	2006-05-31	2009-06-03	艾博特公司	作为大麻素受体配体的新型化合物及其用途
EP2068872A1 (en)	2006-09-08	2009-06-17	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
CN101765594A (zh)	2007-03-28	2010-06-30	雅培制药有限公司	作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物
US7872033B2 (en) *	2007-04-17	2011-01-18	Abbott Laboratories	Compounds as cannabinoid receptor ligands
CN101711253A (zh) *	2007-05-18	2010-05-19	雅培制药有限公司	用作大麻素受体配体的新化合物
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US9193713B2 (en) *	2007-10-12	2015-11-24	Abbvie Inc.	Compounds as cannabinoid receptor ligands
BRPI0820481A2 (pt)	2007-11-20	2015-06-16	Janssen Pharmaceutica Nv	Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina
FR2931108B1 (fr) *	2008-05-15	2011-01-07	Peugeot Citroen Automobiles Sa	Limiteur de vitesse a indicateur de vitesse limite a deplacement manuel, pour vehicule automobile
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8846730B2 (en) *	2008-09-08	2014-09-30	Abbvie Inc.	Compounds as cannabinoid receptor ligands
TW201016692A (en) *	2008-09-16	2010-05-01	Abbott Lab	Novel compounds as cannabinoid receptor ligands
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
PA8854001A1 (es) *	2008-12-16	2010-07-27	Abbott Lab	Compuestos novedosos como ligandos de receptores de canabinoides
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
NZ601655A (en)	2010-01-22	2014-10-31	Acetylon Pharmaceuticals Inc	Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
PL2640709T3 (pl)	2010-11-16	2016-10-31		Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania”
MX348131B (es)	2011-02-25	2017-05-26	Merck Sharp & Dohme	Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CN103804362A (zh) *	2012-11-12	2014-05-21	韩文毅	一类治疗糖尿病的化合物及其用途
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2015054099A1 (en)	2013-10-08	2015-04-16	Acetylon Pharmaceuticals, Inc.	Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
ES2862126T3 (es)	2013-10-10	2021-10-07	Acetylon Pharmaceuticals Inc	Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
US10660890B2 (en)	2013-10-24	2020-05-26	National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr)	Treatment of polycystic diseases with an HDAC6 inhibitor
ES2806258T3 (es)	2013-12-03	2021-02-17	Acetylon Pharmaceuticals Inc	Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
US9464073B2 (en)	2014-02-26	2016-10-11	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en)	2014-07-07	2017-02-27	Acetylon Pharmaceuticals Inc	Treatment of leukemia with histone deacetylase inhibitors
US9937174B2 (en)	2014-12-05	2018-04-10	University of Modena and Reggio Emilia	Combinations of histone deacetylase inhibitors and bendamustine
US10272084B2 (en)	2015-06-01	2019-04-30	Regenacy Pharmaceuticals, Llc	Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
TW201718516A (zh)	2015-06-08	2017-06-01	艾斯特隆製藥公司	組蛋白去乙醯酶抑制劑之晶形
CN107922352B (zh)	2015-06-08	2021-08-06	埃斯泰隆制药公司	制备蛋白质脱乙酰酶抑制剂的方法
WO2017184774A1 (en)	2016-04-19	2017-10-26	Acetylon Pharmaceuticals, Inc.	Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
ES2929032T3 (es)	2016-08-08	2022-11-24	Acetylon Pharmaceuticals Inc	Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298B1 (en)	2016-12-20	2026-03-11	Merck Sharp & Dohme LLC	Antidiabetic spirochroman compounds
EP3920885A1 (en)	2019-02-08	2021-12-15	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
CN110128305A (zh) *	2019-05-10	2019-08-16	天津大学	二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途
CN116813497B (zh) *	2023-08-31	2023-11-14	天津匠新致成科技有限公司	一种酰胺类化合物及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1198551A (en) *	1968-01-22	1970-07-15	Union Pharma Scient Appl	New Nicotinuric Acid Derivatives
DE2334266A1 (de) *	1972-07-07	1974-01-31	Hisamitsu Pharmaceutical Co	Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidin-2,4 (1h, 3h)-dione
JPS5069096A (da) *	1973-10-25	1975-06-09
US5264437A (en) *	1992-03-20	1993-11-23	Syntex (U.S.A.) Inc.	Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
NO311614B1 (no)	1996-10-01	2001-12-17	Janssen Pharmaceutica Nv	Substituerte diamino-1,3,5-triazinderivater
US6022884A (en) *	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
AU1507199A (en) *	1997-12-15	1999-07-05	Yamanouchi Pharmaceutical Co., Ltd.	Novel pyrimidine-5-carboxamide derivatives
AU751573C (en)	1998-03-27	2003-10-09	Janssen Pharmaceutica N.V.	HIV inhibiting pyrimidine derivatives
US6417185B1 (en) *	1998-06-19	2002-07-09	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
JP3635238B2 (ja)	1998-11-10	2005-04-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖの複製を阻害するピリミジン類
NZ513639A (en)	1999-04-15	2004-02-27	Bristol Myers Squibb Co	Cyclic protein tyrosine kinase inhibitors

2002
- 2002-10-29 CN CNA028219171A patent/CN1582277A/zh active Pending
- 2002-10-29 DK DK02790304T patent/DK1442019T3/da active
- 2002-10-29 PL PL02368917A patent/PL368917A1/xx not_active Application Discontinuation
- 2002-10-29 CA CA002463821A patent/CA2463821A1/en not_active Abandoned
- 2002-10-29 KR KR1020047004827A patent/KR20050040814A/ko not_active Abandoned
- 2002-10-29 US US10/493,454 patent/US7183288B2/en not_active Expired - Fee Related
- 2002-10-29 ES ES02790304T patent/ES2294190T3/es not_active Expired - Lifetime
- 2002-10-29 IL IL16166102A patent/IL161661A0/xx unknown
- 2002-10-29 AT AT02790304T patent/ATE375331T1/de active
- 2002-10-29 EP EP02790304.6A patent/EP1442019B8/en not_active Expired - Lifetime
- 2002-10-29 DE DE60222921T patent/DE60222921T2/de not_active Expired - Lifetime
- 2002-10-29 EA EA200400615A patent/EA007578B1/ru not_active IP Right Cessation
- 2002-10-29 MX MXPA04004177A patent/MXPA04004177A/es active IP Right Grant
- 2002-10-29 BR BR0213791-7A patent/BR0213791A/pt not_active IP Right Cessation
- 2002-10-29 PT PT02790304T patent/PT1442019E/pt unknown
- 2002-10-29 HU HU0402330A patent/HUP0402330A3/hu unknown
- 2002-10-29 AU AU2002363174A patent/AU2002363174B2/en not_active Ceased
- 2002-10-29 WO PCT/EP2002/012067 patent/WO2003037869A1/en not_active Ceased
- 2002-10-29 NZ NZ531855A patent/NZ531855A/en not_active IP Right Cessation
- 2002-10-29 JP JP2003540151A patent/JP2005507419A/ja active Pending
2004
- 2004-05-07 NO NO20041891A patent/NO327097B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE60222921D1 (de)	2007-11-22
HUP0402330A3 (en)	2010-03-29
US20050176713A1 (en)	2005-08-11
WO2003037869A1 (en)	2003-05-08
JP2005507419A (ja)	2005-03-17
PT1442019E (pt)	2007-12-11
ATE375331T1 (de)	2007-10-15
DE60222921T2 (de)	2008-08-07
CA2463821A1 (en)	2003-05-08
BR0213791A (pt)	2004-12-07
EA007578B1 (ru)	2006-12-29
CN1582277A (zh)	2005-02-16
EA200400615A1 (ru)	2004-08-26
MXPA04004177A (es)	2004-09-06
ES2294190T3 (es)	2008-04-01
US7183288B2 (en)	2007-02-27
KR20050040814A (ko)	2005-05-03
AU2002363174B2 (en)	2008-09-25
EP1442019B1 (en)	2007-10-10
NO20041891L (no)	2004-05-07
EP1442019B8 (en)	2013-10-30
NZ531855A (en)	2005-12-23
HUP0402330A2 (hu)	2005-02-28
PL368917A1 (en)	2005-04-04
NO327097B1 (no)	2009-04-20
EP1442019A1 (en)	2004-08-04
IL161661A0 (en)	2004-09-27

Publication	Publication Date	Title
EP1442019B8 (en)	2013-10-30	Amide derivatives as glycogen synthase kinase 3-beta inhibitors
MXPA04004176A (es)	2004-09-06	Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa.
WO2003037891A8 (en)	2003-09-04	Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
EA200970655A1 (ru)	2009-12-30	6-замещенные пиримидины, ингибирующие вич
WO2003024967A3 (en)	2003-09-04	Indolizines as kinase protein inhibitors
TW200519115A (en)	2005-06-16	Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
WO2001055116A3 (en)	2001-12-27	Quinoline derivatives and their use as aurora 2 kinase inhibitors
KR20050085991A (en)	2005-08-29	Compounds exhibiting thrombopoietin receptor agonism
PE20081393A1 (es)	2008-11-26	Derivados de quinolina como inhibidores de csf-1r
MY189572A (en)	2022-02-17	Hiv replication inhibiting pyrimidines
JO2460B1 (en)	2009-01-20	Triso-pyrimidine derivatives acting as contraindications to the glycogen kinase-3 enzyme
WO2006067614A3 (en)	2007-01-04	Heteroaromatic derivatives useful as anticancer agents
NO20071234L (no)	2007-05-08	Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin
CY1114908T1 (el)	2016-12-14	Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
TW200517106A (en)	2005-06-01	Sustained release pharmaceutical compositions
MX2010000658A (es)	2010-03-26	Derivados de pirimidina 934.
MXPA04002495A (es)	2004-05-31	Compuestos de imidazopiridin como moduladores del receptor 5-ht4.
TW200626561A (en)	2006-08-01	HIV inhibiting 5-substituted pyrimidines
YU58301A (sh)	2004-05-12	2-aminopiridini koji sadrže supstituente sa kondenzovanim prstenom
TW200606154A (en)	2006-02-16	Mercaptoimidazoles as CCR2 receptor antagonists
TNSN08023A1 (en)	2009-07-14	Novel polysubstituted 1,1-pyridinyl aminocyclopropanamine derivatives, method for preparing same and pharmaceutical compositions containing same
TW200606155A (en)	2006-02-16	Mercaptoimidazoles as CCR2 receptor antagonists
KR950704331A (ko)	1995-11-17	세펨 화합물 및 그의 약제학적 조성물(cephem compounds and their pharmaceutical compositions)
DE60214554D1 (de)	2006-10-19	Derivate von 3-phenyl-n-(2-(4-benzyl)piperidin-1-yl)ethyl) acrylamid mit ccr-3-rezeptor antagonistischer wirkung zur verwendung bei der behandlung von entzündungen und allergischen leiden
TW200618797A (en)	2006-06-16	Isatin compounds and pharmaceutical composition comprising the same